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significantly attenuated (i.e. improved) immediate recall (p=0.014) but not delayed recall. None of the 
other cognitive domains was modulated by either nicotine abstinence or GSK1034702. These findings 
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Abstract
Episodic memory deficits are a core feature of neurodegenerative disorders. Muscarinic M1 receptors play
a critical role in modulating learning and memory and are highly expressed in the hippocampus. We
examined the effect of GSK1034702, a potent M1 receptor allosteric agonist, on cognitive function, and
in particular episodic memory, in healthy smokers using the nicotine abstinence model of cognitive
dysfunction. The study utilized a randomized, double-blind, placebo-controlled, cross-over design in
which 20 male nicotine abstained smokers were tested following single doses of placebo, 4 and 8 mg
GSK1034702. Compared to the baseline (nicotine on-state), nicotine abstinence showed statistical signifi-
cance in reducing immediate (p=0.019) and delayed (p=0.02) recall. GSK1034702 (8 mg) significantly
attenuated (i.e. improved) immediate recall (p=0.014) but not delayed recall. None of the other cognitive
domains was modulated by either nicotine abstinence or GSK1034702. These findings suggest that
stimulating M1 receptor mediated neurotransmission in humans with GSK1034702 improves memory
encoding potentially by modulating hippocampal function. Hence, selective M1 receptor
allosteric agonists may have therapeutic benefits in disorders of impaired learning including Alzheimer’s
disease.
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Introduction
Neurodegenerative disorders, including Alzheimer’s
disease (AD) and schizophrenia, are associated with
impairment across a range of cognitive domains,
although both disorders are characterized clinically
by substantial impairment in episodic memory. This
memory impairment underlies significant difficulties
in activities of daily living including self-care and,
consequently, there is an urgent need for therapies to
improve memory in both AD and schizophrenia. In
both disorders, the impairment in episodic memory
reflects disruption to cholinergically modulated
neurocognitive networks for memory that centre on
the hippocampus (Hasselmo & Sarter, 2011) ; albeit
through different disease specific pathological pro-
cesses. Within these memory networks there is
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increasing evidence for impairment in muscarinic M1
receptors and their associated signalling pathways. In
AD, reductions in M1 or M1/M4 receptors have
been demonstrated in post-mortem autoradiography
(Rodrı́guez-Puertas et al. 1997) and single photon
emission computed tomography imaging (Pakrasi et al.
2007) studies. Although not all studies have been
consistent and some report a compensatory increase
in M1 receptors (Overk et al. 2010), M1 receptor signal
transduction-related markers or function are re-
portedly decreased or impaired in AD (Ferrari-DiLeo
et al. 1995; Potter et al. 2011; Tsang et al. 2006, 2007).
Similarly, several post-mortem [3H]pirenzepine-
binding studies have demonstrated reductions in
M1/M4 receptors in specific brain regions, including
the hippocampus, in patients with schizophrenia
(Crook et al. 2000, 2001; Dean et al. 2002; Deng &
Huang, 2005). Hence, pharmacological modulation of
muscarinic M1 receptors may provide a therapeutic
opportunity for amelioration of episodic memory im-
pairment in both disorders.
Within neurocognitive networks for memory, post-
synaptic M1 receptors are predominantly expressed
throughout the cortex and hippocampus (Levey et al.
1991). Activation of M1 receptors increases ERK1/2
phosphorylation (Thiels & Klann, 2001), amplifies
N-methyl-D-aspartate receptor mediated currents
(Marino et al. 1998) and hippocampal long-term
potentiation (LTP; Buchanan et al. 2010; Fernández de
Sevilla et al. 2008), all of which are critical biochemical
and cellular mediators of learning and memory
(Malenka & Bear, 2004). Pre-clinical in vivo studies
using selective M1 receptor agonists have shown evi-
dence for direct links between M1 receptor activation
and improved learning and memory (Brandeis et al.
1995; Fisher et al. 2002; Ruske & White, 1999 ; Vincent
& Sepinwall, 1992 ; Watt et al. 2011).
Despite their therapeutic potential, themagnitude of
benefits to memory or cognitive function in humans
produced by muscarinic agonists has been modest and
often limited by peripheral M2 and/or M3 muscarinic
receptor-related side-effects, such as severe gastroin-
testinal disturbance. The recent discovery that M1
receptors possess an allosteric (or ectopic) site that is
non-conserved across muscarinic acetylcholine recep-
tor (mAChR) subtypes has provided the opportunity
to develop M1 receptor agonists with true receptor
selectivity (Spalding et al. 2002) and therefore of great
potential as memory enhancing agents in humans. In
animals, the selective M1 receptor allosteric agonist
AC-260584 has been shown to improve learning and
memory (Bradley et al. 2010; Vanover et al. 2008).
However, it is unknown if similar pro-cognitive effects
can be observed in humans due to the paucity of
ligands available for probing muscarinic receptor sub-
types, including the M1 receptor.
GSK1034702 is a selective M1 receptor allosteric
agonist, being developed for the treatment of cognitive
dysfunction in neurodegenerative disorders. It be-
longs to the series of novel N-substituted benzimida-
zolones recently described (Budzik et al. 2010; Huiban
et al. 2011). In vivo, an isomer of GSK1034702 (i.e.
compound 5; Budzik et al. 2010) enhanced cell firing in
the CA1 region of the rat hippocampus and reversed
the scopolamine-induced amnesia in the hippocam-
pus dependent passive avoidance task of learning in a
dose-related manner (Budzik et al. 2010). Using similar
methods, GSK1034702 caused a concentration depen-
dent increase of hippocampal CA1 neuronal firing
rate, which persisted following repeated treatment
(7 d) and reversed the scopolamine-induced amnesia
in the passive avoidance task following both acute and
sub-chronic (7 d at 6 mg/kg.d) treatment with chal-
lenge doses of 1, 3 or 10 mg/kg (see Supplementary
Material and Supplementary Figs. S1 and S2).
The aim of this study was to investigate, for the first
time, the acute effects of GSK1034702 on episodic
memory as well as more general aspects of cognitive
function in humans. The pro-cognitive effects of
GSK1034702 were tested in healthy adult smokers who
had been abstinent from nicotine (i.e. nicotine absti-
nence model of cognitive impairment). We used the
nicotine abstinence model of cognitive impairment
because : (a) synergistic interactions between muscari-
nic and nicotinic receptors at both a molecular and
behavioural level have been reported (Ellis et al. 2006;
Greenwood et al. 2009) ; (b) nicotine abstinence (for at
least 12 h) in chronic smokers can reduce baseline
cognitive function, including memory, as previously
demonstrated (Myers et al. 2008).The primary hy-
pothesis was that the M1 allosteric agonist GSK1034702
would attenuate the nicotine abstinence-induced
impairments in episodic memory. The effects of
GSK1034702 on other aspects of cognitive function
shown to be relevant to AD and schizophrenia were
then investigated in exploratory analyses.
Method
Subjects
Twenty otherwise healthy male nicotine abstinent
smokers [mean age=32.7 yr ; age range 19–54 and
mean body mass index (BMI)=24.9 ; BMI range
20.2–28.1] were recruited for this study. Subjects were
included in the study if they smoked on average o10
cigarettes per day for at least 1 yr. All participants
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had no history of psychiatric disorders (as assessed by
the Mini-International Neuropsychiatric Interview),
neurological disorders (including learning disorders),
cardiovascular, liver, respiratory or gastrointestinal
disorders and substance abuse, based on a physical
examination and a clinical and psychiatric interview
by a physician. Subjects were also free of any drugs of
abuse, prescription medication and non-prescription
medications including vitamins, herbal and dietary
supplements. All participants gave written informed
consent for participation in the study, which was ap-
proved by the Welwyn Clinical Pharmacology Ethics
Committee, University of Hertfordshire, UK.
Design
The study utilized a randomized, double-blind,
placebo-controlled, cross-over design in which each
participant was tested following three single dose
treatment conditions (placebo, 4 mg GSK1034702 and
8 mg GSK1034702).
Procedure
All subjects underwent screening 30 d before the study
began at the GSK Clinical Unit Cambridge (CUC). In
this screening session, the inclusion and exclusion
criteria described above were applied and the subjects
practised the cognitive assessments (although no data
from these assessments were used in the study analy-
sis). Subjects who satisfied screening were then
randomized to placebo, 4 mg GSK1034702 or 8 mg
GSK1034702. The three treatment sessions were sep-
arated by a minimum 1 wk washout period. Each
study treatment session was given within a nicotine
abstinence model. In this model, subjects were as-
sessed across two study days (day 1 and day 2).
On day 1, subjects were administered placebo at
approximately 09 :00 hours and, approximately 5 h
later, baseline cognitive assessments and mood and
craving questionnaire assessments were completed,
while being allowed to smoke cigarettes ad libitum
until midnight (i.e. nicotine ‘on-state’). Subjects were
housed at the CUC and were escorted by a staff
member to a smoking area. On day 2, pre-drug cog-
nitive testing and questionnaire assessments of mood
and craving were performed in the nicotine ‘abstinent
state’ at approximately 08 :00 hours. On completion,
subjects were dosed with either placebo or
GSK1034702 and post-dose cognitive testing and
mood/craving measurements were conducted be-
tween approximately 5 and 6 h post treatment to
coincide with the time window corresponding to the
highest exposure of GSK1034702 in plasma (2–6 h;
tmax ; 2–3 h). Cognitive and questionnaire assessments
were performed approximately 14 h following
nicotine abstinence. In addition to cognitive testing,
electrophysiological recording was conducted be-
tween 3 and 4.5 h post treatment and these findings
are reported elsewhere.
Cognitive assessments
Episodic memory was assessed using the International
Shopping List Test (ISLT). The ISLT is a 12-word, three
trial verbal list learning test. In this task, subjects were
read a list of 12 words. Each word was a concrete noun
and described an item of food commonly eaten. The
experimenter asked the subjects : ‘ I am going to read to
you a list of items I want you to get from the super-
market/store/market/shop etc. ’. After the 12 words
were read, the subjects were asked to recall as many of
the words as they could. When they could recall no
more words, the same list was read a second time with
the words in the same order after the same instruction.
This process was repeated three times. At the com-
pletion of the computerized battery, subjects were
asked to recall as many of the items as they could from
the shopping list following a delay of 20 min. This
provides a measure of delayed recall. The primary
performance measure from this test is the total num-
ber of words recalled across the three learning trials
(total recall) and the total words recalled on the de-
layed recall trial.
In addition to memory, executive function was
assessed using the Groton maze learning task, psy-
chomotor function was assessed using the CogState
detection task, visual attention was assessed using the
CogState identification task and working memory was
assessed using the one back working memory test.
These tests have been described in detail elsewhere
(Fredrickson et al. 2008; Thompson et al. 2011).
Mood and craving assessments
Changes in mood were examined using the Visual
Analogue Mood Scales (VAMS) (Bond & Lader, 1974).
The VAMS consist of 16 bipolar scales, anchored at
each end of a 100 mm line. Subjects placed a mark on
each line that best described their current mood state.
The scales were reduced to three subscales to assess
alertness, contentedness and calmness. Nicotine with-
drawal was assessed using the Minnesota Nicotine
Withdrawal Scale – Revised (MNWS-R; Hughes &
Hatsukami, 2005). The MNWS-R is a shorter version of
the Minnesota Nicotine Withdrawal Scale, consisting
of a self-report scale divided into seven items, each
representing a specific state of the nicotine withdrawal
M1 receptor modulation of cognition 723
syndrome (e.g. restlessness, desire to smoke, irrita-
bility).
Safety and tolerability
The following safety and tolerability endpoints were
monitored: adverse events (AEs) ; 12-lead electrocar-
diogram (ECG); Holter monitoring ; vital signs (blood
pressure, heart rate, respiration rate and body tem-
perature) ; clinical laboratory evaluations (haema-
tology, clinical chemistry, urinalysis and spirometry).
Pharmacokinetics
Blood samples were collected at regular intervals for
pharmacokinetic analysis.
Statistics
The effects of abstinence on each cognitive task were
examined using a mixed effect analysis of covariance
(ANCOVA) model with subject as a random effect and
period (i.e. day) as a fixed effect. Treatment com-
parisons for each cognitive taskwere examined using a
mixed effect ANCOVA model, with subject as a ran-
dom effect, period and treatment as fixed effects and
baseline as a covariate. For all comparisons, the level of
probability required for significance was set at 0.05.
The significance level at which each of the compari-
sons was tested was at the 5% level. No adjustments
for multiplication were performed because : (a) even
though multiple outcome measures were used, per-
formance on cognitive tests is highly correlated and
therefore corrections that assume independence are
too conservative ; (b) the current study is one of the
first of its kind and therefore we consider the outcomes
to be hypothesis generating; (c) measures of effect size
were computed for all comparisons and effects that
were trivial in magnitude (d<0.2) were not interpreted
irrespective of statistical significance. Confidence in-
tervals (CI) are shown, where ‘0’ represents no effect,
as well as p values and Cohen’s ‘d ’.
Results
Safety and tolerability
GSK1034702 was well tolerated. The majority of AEs
thought to be related to GSK1034702 were rated as
mild severity, indicating no effect on routine activities
of daily living. No subjects were withdrawn due to
drug-related AEs. Although numbers in this study
were small, muscarinic side-effects appeared to be
dose-related with only gastrointestinal symptoms
(salivary hypersecretion, abdominal pain and diar-
rhoea) reported at the 4 mg dose and non-gastrointes-
tinal symptoms (headache, dizziness, lacrimination,
flushing, hyperhidrosis and body temperature
changes) appearing at the 8 mg dose. Gastrointestinal
AEs were reported by 10% of subjects at the 4 mg dose
and by 18% at the 8 mg dose (see Table 1).
Table 1. Treatment-related adverse effects
Most frequent AEs
Placebo, N=21 4 mg, N=21 8 mg, N=22
n (%) n (%) n (%)
Any AE 7 (33) 8 (38) 14 (64)
Any AE related to investigational product 2 (10) 4 (19) 12 (55)
Gastrointestinal
Any event 0 2 (10) 4 (18)
Salivary hypersecretion 0 1 (5) 3 (14)
Abdominal pain 0 1 (5) 0
Nausea 0 0 1 (5)
Flatulence 0 0 1 (5)
Non-gastrointestinal
Any event 0 2 (10) 4 (18)
Headache 3 (14) 2 (10) 3 (14)
Fatigue 1 (5) 2 (10) 1 (5)
Hyperhidrosis 0 0 3 (14)
Feeling of body temperature changes 0 0 2 (9)
Lacrimation 0 0 1 (5)
Flushing 0 0 1 (5)
AE, Adverse event.
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No clinically significant abnormal ECG findings or
Holter interpretations were reported during the study.
No corrected QT (QTc) values>480 ms were reported
although two subjects (one each in the 4 and 8 mg
treatment groups) had QTcB changes from baseline,
which were >30 to f60 ms. Two subjects had vital
signs of potential clinical importance without any
symptoms. One subject had low diastolic blood
pressure (44 mmHg) recorded during treatment with
placebo and another had low diastolic blood pressure
(44 mmHg) during treatment with 8 mg GSK1034702.
Both subjects had low baseline diastolic blood press-
ure so these values were considered normal. No ab-
normal respiration or temperature changes were
reported. The clinical laboratory findings showed no
clinically significant abnormalities.
Cognitive function
The effect of nicotine abstinence on cognitive function
Nicotine abstinence significantly reduced perform-
ance on the immediate (d=0.63 ; 95% CI x1.13 to
x0.0.11 ; p=0.02) and delayed (d=0.62 ; 95% CIx1.14
to x0.0.11 ; p=0.02) recall trials of the ISLT compared
to the nicotine on-state. No statistically significant
effects of nicotine were observed for the detection
(d=0.16), identification (d=0.07), one back working
memory (d=x0.07) and Groton maze learning test
(d=0.16).
Effect of GSK1034702 on cognitive function in the nicotine
abstinence model
It was found that 8 mg GSK1034702 significantly im-
proved immediate recall in the ISLT (i.e. number of
correct responses ; 95% CI 0.16–1.38 ; p=0.014) com-
pared to placebo (Figs. 1 and 2), but had no effect on
delayed recall. GSK1034702 (4 and 8 mg) had no
significant effects on any of the other cognitive tasks
(Fig. 2 and Table 2).
Mood and craving
No significant differences were noted between the
three treatments for the VAMS alertness, calmness and
contentedness factors or withdrawal symptoms mea-
sured by the MNWS-R. However, subjects reported a
greater desire or craving to smoke (95% CI 0.54–1.71 ;
p=0.0007) and overall had greater withdrawal symp-
toms (i.e. MNWS-R total score ; 95% CI 0.39–3.32 ;
p=0.0154) under all treatment conditions in the nic-
otine ‘abstinent state’ compared to the nicotine ‘on-
state’.
Pharmacokinetics
Following oral administration of 4 and 8 mg
GSK1034702, the mean tmax was observed 2.3–3.5 h
after dosing, with individual tmax values ranging from
1 to 6 h after dosing.
Discussion
The paucity of selective agonists and antagonists for
cholinergic muscarinic receptor subtypes has been a
major obstacle in elucidating the precise role of these
receptors in modulating cognitive processes. In this
study, we examined the effects of GSK1034702, a
potent M1 receptor allosteric agonist, on cognitive
function in abstinent smokers. The key finding of the
study was that the M1 allosteric agonist GSK1034702
attenuated the abstinence-induced impairments in
episodic memory (immediate recall) but had no effect
on ‘baseline’ cognitive function.
Data that support the argument that the effect of
GSK1034702 on episodic memory reflects selective
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Fig. 1. International shopping list task. (a) Immediate recall ;
(b) delayed recall. *p<0.05 for difference between nicotine
‘on-state’ and nicotine ‘abstinent state’. **p<0.05 for
treatment difference in the nicotine ‘abstinent state’. Data
expressed as means¡S.E.M.
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activation of the muscarinic M1 receptor stem from the
pharmacology of GSK1034702. When tested at human
recombinant M1 receptors in the fluorometric imaging
plate reader (FLIPR) assay, which measures Ca2+
mobilization, an isomer of GSK1034702 (i.e. com-
pound 5) showed potent M1 agonist activity
(pEC50=8.1) and good selectivity against all four re-
ceptor human muscarinic receptor subtypes (>100
fold selective for hM1 over hM2-M5 ; Budzik et al. 2010).
Similarly, GSK1034702 was a potent agonist at hM1
receptors (pEC50=8.1) and displayed at least 100-fold
selectivity over hM2–5 receptors. GSK1034702 also
demonstrated partial agonist activity (intrinsic activity
y0.6) at rat, marmoset and human native tissue M1
receptors in a guanosine 5k-O-[c-thio]triphosphate
([35S]GTPcS) binding assay as previously described
(Salah-Uddin et al. 2008). The agonist activity of
GSK1034702 was maintained in post-mortem human
cortex from controls and AD patients, as measured
using [35S]GTPcS binding (pEC50 values of 7.0 in con-
trol tissue and 7.5 and 7.0 in mild and severe disease
tissue samples, respectively).
Site-directed mutagenesis of key amino acid resi-
dues on hM1 receptors and the FLIPR assay were
also used to establish whether GSK1034702 activates
hM1 receptors through a site distinct to that of the
orthosteric site agonist acetylcholine (ACh). The
potency of ACh to activate the hM1 receptor mutated
at the orthosteric site (Tyr381Ala ; Y381A) was 1000-fold
lower than its potency to activate the wild-type
receptor. In contrast, the potency of GSK1034702 was
not significantly affected by this point mutation (pEC50
values of 7.5 and 7.7, respectively). Another mutation
in the orthosteric binding site, Asn382Ala (N382A), also
reduced the potency of Ach (>30-fold), as compared
to wild-type but did not significantly affect that of
GSK1034702 (pEC50 values of 7.2 and 7.7, respectively).
In contrast, a mutation in transmembrane domain 2
(Phe77Ile ; F77I) significantly reduced the potency of
GSK1034702 (pEC50 values of 6.8 vs. 7.7) without
altering the potency of Ach (see Supplementary
Material and Supplementary Table S1). These data
suggest that GSK1034702 functions through a site on
the hM1 receptor that is distinct to that of ACh.
Overnight nicotine abstinence was associated with a
selective impairment in episodic memory (immediate
and delayed recall) as measured with the CogState
ISLT. No impairments were observed on other cogni-
tive tasks probing attention, working memory and
executive function. The failure to impair other cogni-
tive domains may be related to the study sample (i.e.
smokers who smoked o10 cigarettes per day for at
least 12 months). Previous studies have reported
abstinence-induced impairments in other domains,
including attention, working memory and executive
function, in heavier smokers (i.e. smokers who
smoked o15 cigarettes per day for 12 months ; Myers
et al. 2008). While the present study comprised lighter
smokers, they reported greater desire or craving to
smoke and overall reported more withdrawal
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Fig. 2. Effect sizes for treatment-related differences (change from baseline) in task performance. Zero value indicates no change.
Note : Shopping list recall (delayed recall), shopping list task (immediate recall).
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symptoms following nicotine abstinence suggesting
that the overnight nicotine abstinence induced the
desired physiological effect. Alternatively, it is poss-
ible that the discrepancy between the current study
and the study byMyers et al. (2008) could be explained
by other factors, such as sample size and the type of
cognitive tasks. The latter study had a slightly larger
sample size (n=25) and included different cognitive
tasks to probe attention (continuous performance
task), working memory (2-back) and executive func-
tion (arithmetic test). It is possible that these tasks
were more demanding and hence more susceptible to
abstinence induced impairment.
Animal studies have provided insights into the
precise role of M1 receptors on cognitive function.
Studies using muscarinic M1 receptor knockout mice
have suggested that M1 receptors are not essential for
memory formation or initial stability of memory in the
hippocampus. For example, Miyakawa et al. (2001) did
not observe global impairments in hippocampus-
dependent cognitive tasks probing spatial reference
memory (Morris water maze) or fear learning
(contextual fear conditioning). Slight impairments
were noted in auditory-cued fear conditioning and
working memory measured using the eight-arm radial
maze, but these were thought to be caused by the hy-
peractivity phenotype observed in the M1 receptor
knockout mice (Miyakawa et al. 2001). A subsequent
study also reported no global impairments in hippo-
campus-dependent cognitive tasks but, rather, selec-
tive deficits on tasks requiring interaction between the
hippocampus and cortex (Anagnostaras et al. 2003).
Specifically, M1 receptor mutant mice showed impair-
ments in non-matching to sample tasks probing
working memory and consolidation (win-shift radial
arm and social discrimination learning), while having
no effects or improving performance on matching to
sample tasks probing learning (i.e. contextual fear
conditioning and Morris water maze). These findings
have been interpreted in the context of network mod-
els describing cholinergic function in memory proces-
sing (Buzsaki, 1989 ; Hasselmo, 1999). According to
these models, cholinergic signals function as a switch
between inflow (i.e. encoding) and outflow (recall)
Table 2. Treatment-related differences in cognitive performance in the nicotine ‘abstinent state’
Comparison Effect size (Cohen’s d) LS mean test LS mean reference 95% CI p value S.D.
Detection task : speed of performance
4 mg – PBO x0.32 2.46 2.46 x0.93 to 0.30 0.31 0.03
8 mg – PBO x0.12 2.46 2.46 x0.71 to 0.47 0.68
8 mg – 4 mg 0.19 2.46 2.45 x0.38 to 0.77 0.50
Groton maze learning test : total error rate
4 mg – PBO 0.11 37.5 36.34 x0.46 to 0.68 0.69 10.45
8 mg – PBO 0.06 37.0 36.34 x0.50 to 0.63 0.82
8 mg – 4 mg x0.05 37.0 37.49 x0.61 to 0.52 0.87
Identification task : speed of performance
4 mg – PBO 0.25 2.65 2.64 x0.28 to 0.78 0.34 0.04
8 mg – PBO x0.12 2.64 2.64 x0.66 to 0.41 0.64
8 mg – 4 mg x0.37 2.64 2.65 x0.91 to 0.17 0.17
International shopping list recall (delayed recall) : number of correct responses
4 mg – PBO x0.24 8.29 8.73 x0.78 to 0.29 0.36 1.80
8 mg – PBO 0.11 8.93 8.73 x0.41 to 0.63 0.67
8 mg – 4 mg 0.35 8.93 8.29 x0.16 to 0.87 0.17
International Shopping List Task (immediate recall) : number of correct responses
4 mg – PBO 0.30 26.75 25.85 x0.32 to 0.92 0.33 2.97
8 mg – PBO 0.77 28.14 25.85 0.16–1.38 0.01
8 mg – 4 mg 0.47 28.14 26.75 x0.14 to 1.08 0.13
One back memory task : accuracy of performance
4 mg – PBO 0.40 1.46 1.42 x0.15 to 0.97 0.15 0.11
8 mg – PBO 0.05 1.42 1.42 x0.50 to 0.61 0.85
8 mg – 4 mg x0.35 1.42 1.46 x0.91 to 0.20 0.21
PBO, Placebo.
Data show treatment related change from pre-dose baseline. Summary statistics are reported [effect size, least square (LS) mean,
overall between-subject S.D., 95% confidence intervals (CI) and p value].
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modes of the hippocampus with M1 receptor stimu-
lation hypothesized to bias processing away from the
hippocampus and to the cortex (Anagnostaras et al.
2003). The authors argued that this model may explain
the deficit in cortex dependent working memory and
consolidation of remote memories because the loss of
M1 receptors in the mutant mice would bias proces-
sing away from the cortex (Anagnostaras et al. 2003).
They also reasoned that the model could explain the
enhancement in acquisition of contextual memories in
the M1 mutant mice because processing bias would be
shifted to the hippocampus processing contextual
memory without interference from previously estab-
lished cortical traces (Hasselmo, 1999).
The findings observed in M1 mutant mice are how-
ever inconsistent with pre-clinical studies that have
examined hippocampal activity and nature of cogni-
tive improvement following in vivo administration of
selective M1 receptor agonists. For example, the M1
receptor allosteric agonist and isomer of GSK1034702
(i.e. compound 5 in the N-substituted benzimidazo-
lone series ; Budzik et al. 2010) was shown to enhance
cell firing in the CA1 region of the hippocampus.
Similarly, we have shown that GSK1034702 caused a
significant increase of hippocampal CA1 neuronal
firing rate, which persisted following repeated treat-
ment (7 d). In support of the latter studies showing
modulation of hippocampal activity, the selective M1
receptor allosteric agonist, AC-260584, has been
shown to improve spatial memory in a hippocampus-
dependent Morris water maze task (Vanover et al.
2008) and visual recognition memory in the novel ob-
ject recognition memory task of working memory
(Bradley et al. 2010) that is reliant on the integrity of
both the cortex (perirhinal cortex) and hippocampus.
Similarly, compound 5 described above (Budzik et al.
2010) and GSK1034702 reversed the scopolamine-
induced amnesia in the hippocampus dependent
passive avoidance task of learning. The findings of the
current study showing improvements in hippocampal
dependent encoding of episodic memory with
GSK1034702 in humans are consistent with the latter
studies in animals. Overall, both pre-clinical and
clinical studies using selective M1 receptor agonists
suggest that M1 receptors are important for hippo-
campus dependent memory formation. These findings
do not support the model proposed by Anagnostaras
et al. (2003) based on their work with M1 receptor
mutant mice, suggesting M1 receptor stimulation
would bias processing away from the hippocampus
and to the cortex (Anagnostaras et al. 2003).
Cholinergic innervation of the hippocampus and
muscarinic M1 receptors is critical for the encoding
of episodic memories (Hasselmo & Sarter, 2011). In
rodents, local infusion of scopolamine into the
hippocampus has been shown to impair encoding of
spatial information (Blokland et al. 1992; Rogers &
Kesner, 2003). In humans, muscarinic receptor an-
tagonists such as scopolamine have been shown to
impair encoding of stimuli for subsequent free recall
and cued recall (Atri et al. 2004; Ellis et al. 2006;
Ghoneim & Mewaldt, 1975, 1977 ; Petersen, 1977).
Herein, we report that selectively activating M1 re-
ceptors with GSK1034702 improved acquisition or
encoding of new memories as shown by an improve-
ment in learning in the immediate recall task. This
is consistent with pre-clinical studies in rodents
showing improvements in learning and memory
with the selective M1 receptor allosteric agonist,
AC-260584 (Bradley et al. 2010; Vanover et al. 2008).
Septohippocampal cholinergic pathways have been
shown to excite hippocampal pyramidal neurons (for
a review, see Nicoll, 1985) and this pathway plays a
critical role in memory functions, including encoding
of episodic memories (for reviews, see Blokland, 1996;
Hasselmo & Sarter, 2011). Muscarinic receptor acti-
vation has also been shown to enhance hippocampal
pyramidal cell spiking response to afferent input (Cole
& Nicoll, 1984 ; Madison & Nicoll, 1984) and physio-
logically released ACh from cholinergic neurons has
been shown to enhance LTP of excitatory synaptic
transmission in the hippocampus through post-
synaptic M1 mAChR activation (Buchanan et al. 2010;
Shinoe et al. 2005). Similar enhancement of hippo-
campal cell firing rate and LTP has also been reported
with the selective allosteric M1 receptor agonists
(Buchanan et al. 2010; Budzik et al. 2010). Furthermore,
ACh release in the hippocampus has been shown to
correlate with improved spatial learning performance
in rats (Fadda et al. 2000). Together, these findings
suggest that the improvements in encoding and
learning following M1 receptor stimulation may be a
consequence of selective enhancement of the respon-
siveness of the hippocampus to afferent input for en-
coding and subsequent consolidation via plasticity
mechanisms including induction of LTP.
The effects of GSK1034702 were specific to episodic
memory encoding, which was impaired following
nicotine abstinence. In contrast, GSK1034702 had no
effects on ‘baseline’ or ‘unimpaired’ cognitive func-
tion (i.e. cognitive processes that were not impaired by
nicotine abstinence, including attention, working
memory and executive function). It is possible that
GSK1034702 may have attenuated these latter cogni-
tive processes if they were also ‘ impaired’. Indeed,
previous studies have shown robust modulation of
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attention and working memory following muscarinic
receptor antagonism with scopolamine (Ellis &
Nathan, 2006 ; Hasselmo & Sarter, 2011), suggesting
that M1 receptor agonists could have positive effects
on attention and working memory. Further studies
are required to determine if GSK1034702 could atten-
uate impaired attention, working memory and execu-
tive function in other models of cognitive dysfunction
(i.e. scopolamine or sleep deprivation) or patients with
AD or schizophrenia.
Episodic memory deficits are the hallmark of
AD and these deficits are more related to learning
(encoding and storage) of information rather than re-
trieval. In this study we provide evidence showing
improvements in episodic memory in an experimental
model of cognitive dysfunction. These findings are
encouraging and suggest that selective M1 agonists
may have efficacy in the treatment of disorders as-
sociated with impaired learning and this warrants
further investigation.
Note
For supplementary material accompanying this paper,
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